^
    Back
    Association details:
    Biomarker:EGFR mutation
    Cancer:Gastric Cancer
    Drug:Gilotrif (afatinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Non Small Cell Lung Cancer)
    New
    Title:

    Afatinib (Giotrif) is accepted for use within NHS Scotland

    Excerpt:
    Afatinib (Giotrif) is accepted for use within NHS Scotland...as monotherapy, for the treatment of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor-naïve adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation(s).
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    ASCO 2021
    Title:

    Matched therapies for advanced gastric cancer based on genotype: A real-world study in China.

    Published date:
    05/19/2021
    Excerpt:
    ...1 (3%) EGFR mutation (received afatinib, cohort F)...Stable disease was observed in the patient in cohort F.